Drug intelligence / Profile preview

SJP-001X

Development stage: Preclinical
Lead developer: Sen-Jam Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SJP-001X is an over-the-counter (OTC) oral combination therapeutic candidate under development by Sen-Jam Pharmaceutical for metabolic health indications, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), and metabolic recovery. Developed using Sen-Jam's proprietary Pleiotropic Anti-Inflammatory Remedies (PAIR) platform, SJP-001X is designed to target chronic low-grade inflammation and metabolic stress upstream. The therapeutic aims to modulate the inflammatory cascade and restore metabolic balance without suppressing the immune system.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on SJP-001X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJP-001X.

Explore the full profile